Is Sana Biotechnology going out of business?

Sana Biotechnology, Inc. (SANA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Sana Biotechnology, Inc. (SANA) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: ROIC: -140.25%

Five questions, kept separate

Survival - Critical

4-6 mo of estimated runway from 2026-06-30, based on $57.1M of cash and short-term investments against $145M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-8.9% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Debt / Equity: 0.48x
• ROIC: -140.25%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.39y
• Shares dilution YoY: 20.30% (YoY)
• Return on Assets: -56.58%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-10.

Price as of 2026-09-07.